When does Saphnelo lose exclusivity in the US?
Saphnelo (anifrolumab) is currently protected by patent rights and other forms of market exclusivity, but the exact date depends on which protection you mean (patent expiration vs. FDA exclusivity). With only the information provided here, there is not enough detail to state a specific “loose exclusivity” date for the US.
What’s the difference between “patent expiry” and “exclusivity”?
In the US, generic and biosimilar entry timing is usually driven by:
- Patent expiration (including possible patent term adjustments and the effect of patent litigation/settlements).
- FDA exclusivity (such as the exclusivity attached to biologics applications), which can delay approval even if some patents expire earlier.
Those schedules can differ, so “exclusivity” in everyday language can mean different dates.
Can biosimilars launch before all patents expire?
Yes. In practice, a biosimilar can sometimes be approved (and in limited cases launched) before every patent tied to the reference product has expired, depending on:
- Whether key patents are still in force,
- Whether patents are “carved out” by litigation outcomes,
- The specific patents listed in the FDA’s publication for biologics.
What I need to give you the actual US date
If you share either:
- the relevant patent numbers (or a link to the patent list you’re using), or
- the specific “exclusivity type” you mean (e.g., biologics exclusivity / clinical trial exclusivity vs. patent expiration),
I can map that to the correct US timing and give you the specific date Saphnelo loses the relevant protection.
Sources: None provided.